Discovery Labs (DSCO) Announces Aerosolized KL-4 Surfactant Chosen for Phase 2a Clinical Trial
More News related to DSCO
- Discovery Labs to Present At the Lazard Healthcare Conference
- Unusual 11 Mid-Day Movers 11/10: CYCL, STEM, DPTR, GSI Higher; DFT, SRZ, ACAS, ALD Lower
- Discovery Labs (DSCO) Announces FDA Has Accepted Review of Surfaxin(r); Sets Target Action Date of April 17, 2009
- Morning Movers 11/10: AIG (AIG) Up On Restrtucted Bailout, Circuit City (CC) Sinks On Bankruptcy
- FDA Establishes Target Action Date of April 17, 2009 for Potential Approval of Discovery Labs' Surfaxin(r)
More News related to FDA
- Johnson & Johnson Pharmaceutical Research & Development (JNJ) Receives FDA Approval for Tapentadol Immediate-Release Tablets
- Ligand Pharma (LGND) Partner GlaxoSmithKline's Granted Accelerated Approval of PROMACTA
- Bioheart (BHRT) Announces CE Marking for TGI 1200(tm) Adult Stem Cell Isolation System
- Targanta Therapeutics (TARG) Receives Mixed FDA Reviews of Investigational Antibiotic Therapy Treatment
- SuperGen (SUPG) Receives Clearance to Begin Clinical Trials With SGI-1776
Discovery Laboratories, Inc. (Nasdaq: DSCO) announces that its proprietary, aerosolized KL-4 surfactant has been selected for a Phase 2a clinical trial in patients with Cystic Fibrosis. The trial is being conducted as an investigator-initiated study under the direction of Dr. Scott H. Donaldson at The University of North Carolina and is funded primarily through a grant provided by the Cystic Fibrosis Foundation.
The trial is designed as a double-blind, randomized study to evaluate whether Discovery Labs' aerosolized KL-4 surfactant is safe and well tolerated in patients with mild to moderate CF lung disease. In addition, the short-term effectiveness of aerosolized KL-4 will be assessed. UNC's Investigational New Drug Application for this study was submitted to the U.S. FDA and went into effect in May 2008. Patient enrollment is expected to begin this fall.
Discovery Laboratories, Inc., together with its subsidiaries, operates as a biotechnology company that develops proprietary surfactant technology as Surfactant Replacement Therapies (SRT) for respiratory disorders and diseases.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
